West Sweden Parkinson Objective Measurement Registry Study (WestPORTS)
Objective: To study a population representative Parkinson’s Disease (PD) patient cohort characterized with objective 6x24h home measurements using the Parkinson Kinetigraph (PKG, Global Kinetics). To…Levodopa-induced dyskinesia in Parkinson’s disease: Sleep matters
Objective: To investigate the relationship between slow wave activity (SWA) of non-rapid eye movement (NREM) sleep, which underlies adjustment of cortical excitability, and levodopa-induced dyskinesias…Intrastriatal Fyn silencing as a gene therapy strategy to manage levodopa induced dyskinesia in a mice model of Parkinson’s disease
Objective: To genetically abrogate Fyn expression to reduce levodopa induced dyskinesia (LID) in the 6-OHDA mice model of Parkinson’s disease (PD), using intrastriatal-injected lentiviral (LV)…Combined administration of A2A receptor antagonist and 5-HT1A/1B receptor agonist reverses neuroinflammation in the 6-OHDA model of Parkinson’s disease
Objective: To investigate whether in a model of Parkinson's Disease (PD), an early treatment with the serotonin 5-HT1A/1B receptor agonist eltoprazine and the adenosine A2A…Levodopa-induced dyskinesias in Parkinson disease: A population-based cohort study in Olmsted County, MN (1991-2010)
Objective: To assess the frequency of dyskinesias in a population based-cohort of Parkinson’s disease patients. Background: Levodopa-induced dyskinesias are complications that may impact quality of…Spatiotemporal patterns of direct and indirect pathway striatal projection neurons in mouse model of Parkinson’s disease and dyskinesia
Objective: To identify patterns of striatal projection neurons (SPN) activities that code for akinetic and dyskinetic movement disorders in a mouse model of hemiparkinsonism and…Interaction between mGluR5 and NR2B is increased in 6-OHDA parkinsonian rats with L-dopa-induced dyskinesiaInteraction between mGluR5 and NR2B is increased in 6-OHDA parkinsonian rats with L-dopa-induced dyskinesia
Objective: In this study, we verified whether the interaction of mGluR5 and NR2B exerts an important effect on the development of LID. Background: L-dopa is…Ondansetron, a highly-selective 5-HT3 receptor antagonist, alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To determine the effectiveness of selective serotonin 3 (5-HT3) receptor blockade at reducing the severity of established, and preventing the development of, dyskinesia. Background:…Assessing the potential cost-effectiveness of ads-5102 (Amantadine HCl) for the treatment of dyskinesia in Parkinson’s disease patients
Objective: This economic evaluation projects the likely cost-effectiveness of ADS-5102 in comparison to the current standard of best supportive care. Background: In August, 2017, the…Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and Parkinson’s Disease: Preliminary report
Objective: We conducted a pilot study to determine the association between the neutrophil to lymphocyte ratio (NLR), he lymphocyte to monocyte ratio (LMR), the levels…
- « Previous Page
- 1
- …
- 29
- 30
- 31
- 32
- 33
- …
- 44
- Next Page »